SCHEDULE 13G/A: BlackRock Maintains Significant 8.1% Stake in SI-BONE, Inc.

BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 8.1% of SI-BONE, Inc.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 5 to its Schedule 13G regarding its beneficial ownership in SI-BONE, Inc.
• As of March 31, 2025, BlackRock beneficially owned an aggregate of 3,423,923 shares of SI-BONE, Inc. common stock.
• This ownership represents 8.1% of the total outstanding common stock of SI-BONE, Inc.
• BlackRock holds sole voting power over 3,375,225 shares and sole dispositive power over 3,423,923 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of SI-BONE, Inc.
• BlackRock Investment Management, LLC, a subsidiary of BlackRock, Inc., is noted as beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing indicating a large institutional investor's continued significant stake, which is generally neutral but can be seen as a slight positive for the issuer as it implies ongoing confidence or at least no immediate divestment.

Positives

• BlackRock, a major institutional investor, maintaining a significant 8.1% stake in SI-BONE, Inc. may signal continued confidence in the company's long-term prospects.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding SI-BONE, Inc.'s future performance or outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a routine disclosure by a major institutional asset manager, BlackRock, Inc., regarding its passive investment position in SI-BONE, Inc., a company operating in the medical device sector. Such filings are common as large funds manage their diversified portfolios.

Comparison to Industry Standards

• This document is a beneficial ownership report (Schedule 13G) and does not contain operational or financial performance metrics that would allow for a direct comparison to industry standards, comparable companies, or projects. It solely details an institutional investor's stake.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.

Key Dates

Keywords

SI-BONE Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Medical Devices, Orthopedics